[1] Davidson's thesis was conducted under the guidance of William Kelley and titled "The Genetic Basis of Hypoxanthine Guanine Phosphoribosyltransferase Deficiency States in Humans.
[3] This subsequently proved that gene therapy in mice could prevent the physical symptoms and neurological damage related to Huntington's disease.
[6] In her final year with the University of Iowa, Davidson co-launched Spark Therapeutics with Jean Bennett to develop "gene-based medicines for a wide range of debilitating diseases" in collaboration with the Children's Hospital of Philadelphia (CHOP).
[8] As the director, Davidson helped Spark launch their first gene therapy program targeting a disease of the central nervous system.
[9] Following this, Davidson was elected to the American Academy of Arts and Sciences[10] and named director of CHOP's underground clinical manufacturing facility in the Colket Translational Research Building.